A Current Practice Snapshot of Atopic Dermatitis Management: Where We Are and Where We Need to Be

FACULTY

Linda F. Stein Gold, MD
Director of Dermatology Research Division Head of Dermatology
Henry Ford Health System
Detroit, Michigan

Luz Fonacier, MD
Head of Allergy
Training Program Director
Winthrop University Hospital
Mineola, New York
Professor of Medicine
SUNY Stony Brook
Stony Brook, New York

Moise L. Levy, MD
Professor of Pediatrics and Medicine (Dermatology)
Dell Children’s Medical School
University of Texas, Austin
Clinical Professor of Dermatology and Pediatrics
Baylor College of Medicine
Pediatric/Adolescent Dermatology
Dell Children’s Medical Center
Austin, Texas

Introduction

The evolving understanding of the pathophysiology of atopic dermatitis (AD) has led to the recent approval of new therapies with novel mechanisms of action, including crisaborole, a topical agent for mild-to-moderate AD, and dupilumab, a systemic agent for moderate-to-severe disease. Despite these advances, however, many clinicians may lack awareness of how to accurately assess disease severity and, subsequently, how to design an appropriate therapeutic strategy for the individual patient when the disease progresses. As an expert panel of the International Eczema Council (IEC) recently observed, “Guidelines for decision making about advancement to systemic therapy are lacking.” To address these gaps in knowledge and practice—and to explore “where we are” with regard to contemporary AD management—a multicomponent CME-certified program was launched in the fall of 2018.

CME/CE-Certified Program

5 live national dermatology conferences

MedQuiz

Participants answer questions

Participants rate their degree of confidence before submitting each answer

A brief scientific explanation of each answer is shown, reinforcing correct responses or explaining incorrect ones

Scores are calculated on the basis of accuracy and degree of confidence and displayed on a leader board

Questions are also made available online to a broader audience of dermatology clinicians (https://tinyurl.com/ADQuiz18)

Module 1: Current Theories of the Pathophysiology of AD

Illustrates the current science of AD pathophysiology and defines levels of AD severity

Module 2: Step Care in AD

Explores the tools available for patient assessment

Module 3: Treatment Strategies for AD

Presents case challenges in managing patients of different ages and with different degrees of AD symptomatology

This supplement outlines the interim findings from pretest and post-test questions of the above educational activities and highlights the following:

Where we are in current practice for atopic dermatitis management

Data from key questions asked during the activities

Where we need to be for optimal atopic dermatitis management

Information on what clinicians should know and how they should apply that knowledge
Exploring Mechanisms of Disease

Questions presented during the interactive modules and MedQuiz activity focused on learners’ general understanding and knowledge of specific aspects of AD pathology.

Where we are

50% of respondents did not know that irritants, such as cigarette smoke, are an undisputed trigger for AD.

Where we need to be

The current model of AD posits a multifactorial pathogenesis involving both an “outside-in” and an “inside-out” process. In this view, symptoms result from a combination of defects in the skin barrier that are exacerbated by dysregulated immune activity. Understanding this principle is important, since treatment for AD in the earlier stages involves topical management (including use of skin hygiene, emollients, and therapeutic lotions or ointments), while in the later stages a systemic approach may be needed to address the underlying inflammatory and allergic processes. Non-lesional AD has a greater response to irritants, including cigarette smoke.

Where we are

Nearly 76% of learners reported that their understanding of the pathophysiological mechanisms contributing to the barrier defect in AD was only “fair” or “poor.”

Where we need to be

When asked about which factors contribute to the skin barrier defect seen in AD, the proportion of learners who identified the correct answer (defects in filaggrin) rose from about 22% (pretest) to nearly 75% after exposure to the education.
Current Concepts in Assessing AD

Learners’ understanding of symptoms and comorbidities of AD was determined, along with their knowledge of tools that can be used to make such assessments.

**Where we are**

Which of the following symptoms do patients with AD typically report is the most bothersome?

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Pretest</th>
<th>Post-test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>16%</td>
<td></td>
</tr>
<tr>
<td>Bleeding</td>
<td>4%</td>
<td></td>
</tr>
<tr>
<td>Itch*</td>
<td>55%</td>
<td>92%</td>
</tr>
<tr>
<td>Pain</td>
<td>25%</td>
<td></td>
</tr>
</tbody>
</table>

% respondents

*Correct answer.

**Where we need to be**

The clinical presentation of AD involves the following:

- **Clinical Presentation:**
  - Pruritus
  - Eczema
  - Sleep disturbance
  - Depression
  - Pain, bleeding, or oozing
  - Psychosocial challenges

Awareness of pruritus is important because treatment must be designed to address this aspect of disease to optimize outcomes and to improve patients’ satisfaction with their therapy.

**Where we are**

In the interactive modules, the majority of learners reported that they did not use any of the listed assessment tools when clinically evaluating patients with AD.

<table>
<thead>
<tr>
<th>Assessment Tool</th>
<th>Number of responses</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADSI</td>
<td>1</td>
</tr>
<tr>
<td>EASI</td>
<td>4</td>
</tr>
<tr>
<td>IGA</td>
<td>5</td>
</tr>
<tr>
<td>Patient-reported outcomes</td>
<td>7</td>
</tr>
<tr>
<td>POEM</td>
<td>6</td>
</tr>
<tr>
<td>DLQI</td>
<td>5</td>
</tr>
<tr>
<td>SASSAD</td>
<td>2</td>
</tr>
<tr>
<td>SCORAD/oSCORAD</td>
<td>2</td>
</tr>
<tr>
<td>Other*</td>
<td>3</td>
</tr>
<tr>
<td>None of these</td>
<td>26</td>
</tr>
</tbody>
</table>

Number of responses (more than one could be chosen)

*Other = Body Surface Area (BSA); Clinician's Global Assessment of Severity (CGAS); Pittsburgh Sleep Quality Index (PSQI). ADSI, Atopic Dermatitis Severity Index; EASI, Eczema Area and Severity Index; IGA, Investigator Global Assessment; POEM, Patient-Oriented Eczema Measure; SASSAD, Six Area, Six Sign Atopic Dermatitis; SCORAD/oSCORAD, (Objective) Scoring Atopic Dermatitis.

**Where we need to be**

Although most patients with AD can be managed effectively with topical agents, a significant number will require a more aggressive approach. The decision to step up to systemic therapy should be made holistically, involving a mix of tools to assess both disease severity and the patient’s overall quality of life. Many tools exist for evaluating these parameters, but most are intended for use in evaluating results of trials and may not be practical in the clinic. No “gold standard” tool has been identified, and only 3 have been adequately validated: EASI, SCORAD, and POEM. Experts recommend applying a mix of tools and strategies for assessment.

- **Pros**
  - Simple to administer
  - Patient (or parent) fills it out in the waiting room before seeing the clinician
  - Takes a few seconds to score
- **Cons**
  - Assesses only frequency of 7 characteristic signs and symptoms
  - Does not assess extent or severity of lesions

**Tool Assessment Items**

- **Pros**
  - Simple to administer
  - Patient (or parent) fills it out in the waiting room before seeing the clinician
  - Takes a few seconds to score
- **Cons**
  - Assesses only frequency of 7 characteristic signs and symptoms
  - Does not assess extent or severity of lesions

Each item on the left is scored by the number of days that symptom has been present over the past week.

- **CDLQI**, Children’s Dermatology Life Quality Index
- **DLQI**, Dermatology Life Quality Index
- **PSQI**, Pittsburgh Sleep Quality Index
Current Concepts in Treating AD

Learners were assessed on their level of understanding of the mechanisms of action of current AD therapies as a way to emphasize the importance of selecting agents that target the pathophysiological disruptions that produce symptoms.

Where we are

Asked which agent targets phosphodiesterase 4 (PDE-4) activity, only about 25% of respondents on the pretest correctly identified crisaborole; after the education, however, more than 80% answered correctly.

Pretest Post-test

25% 80%

Where we need to be

Understanding the mechanism of action of available agents for managing AD will help clinicians identify appropriate treatment choices. Crisaborole inhibits PDE-4 activity, resulting in a reduction in cytokine expression, including IFN-γ, TNF-α, IL-2, IL-4, and IL-31.9

IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.

Where we are

The proportion of learners who knew that dupilumab reduces inflammation in AD by inhibiting Th2 cytokines also rose, from 30% on the pretest to 45% on the post-test, but such results, while encouraging, indicate there is still room to increase awareness about drug mechanisms.

Pretest Post-test

30% 45%

Where we need to be

Dupilumab reduces inflammation in AD by inhibiting Th2 cytokines.

Summary

Atopic dermatitis is a complex disease that can arise at any age, including in very young patients, and that can persist and progress over the course of many years. Most cases are mild-to-moderate in severity and can be managed appropriately and effectively in the primary care setting. However, the underlying pathology of AD can change over time to involve different immune pathways, resulting in more severe symptoms and necessitating a reevaluation of the patient to determine whether referral for more aggressive treatment is needed. Specialists are in a position to offer stepped-up therapy that includes a systemic approach when appropriate. Education that explicates the disease process—and that challenges learners to select optimal treatment for an individual—can be effective, but the range of learner answers submitted by participants in a recent CME program series suggests that more effort is needed to close the educational gaps and improve therapeutic outcomes for patients with AD.

References